Collaboration in more than 46 countries.

You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.

NORTH AMERICA

Canada

United States

LATIN AMERICA

Argentina

Brazil

Mexico

Perú

GLOBAL

CEVA Global

EMEA (REGIONAL)

Denmark

Egypt

France

Germany

Hungary

Italy

Netherlands

Poland

Portugal

Romania

South Africa

Spain

Sweden

Tunisia

Turkey

Ukraine

United Kingdom

ASIA PACIFIC

Asia Pacific (Regional)

CHINA

India

Indonesia

Japan

Korea

Malaysia

Philippines

Share on:

New study confirms the efficacy of Eprecis® 2% in lactating goats after a single subcutaneous administration at the labelled dose

Background information

The health and productivity of dairy goats continue to be impacted by gastrointestinal nematodes and lungworms. Eprinomectin is frequently selected for treatment because it is generally effective and does not require a milk withdrawal period. However, some factors, such as lactation, can have an impact on eprinomectin pharmacokinetics and potentially its efficacy.

How did they prove it?

A new study conducted conjointly by Moredun Scientific, Argenta Germany and Ceva confirms the efficacy of one subcutaneous administration of Eprecis® 2% in lactating goats to address common gastrointestinal nematodes and lungworms infection with the currently labelled dose of 0.1 ml of Eprecis® 2% for 10 kg of bodyweight.

You can read more about it here:

 

This site is registered on wpml.org as a development site.